Goodwin and KPMG will host their 6th Annual Symposium on January 15, 2025, during the 43rd Annual JP Morgan Healthcare Conference.
Life sciences companies have many opportunities to thrive in the face of changing tides. At this year's symposium, we will delve into strategies that enable them to enhance research and development; optimize value from licensing, M&A, and other transactions; and secure capital for growth. By embracing these opportunities, Life sciences companies cannot only avoid getting caught in a riptide but chart new paths to success.
To register for Symposium, please visit our Cvent minisite.
2025 Agenda
- Rachael Bushey, Life Sciences Partner, Co-Chair, Philadelphia Office, Goodwin
- Kristin Ciriello Pothier, US LS Sector Leader, Global Deal Advisory & Strategy HCLS Leader, KPMG
- Beni Surpin, Life Sciences Partner, Goodwin
- Joe Zaccaria, Managing Director, Healthcare & Life Sciences (HCLS), KPMG
- Dan Caron, Chief Executive Officer, Health Universe
- Maria Luisa Pineda, Co-Founder and CEO, Envisagenics
- Enes Hoşgör, Ph.D., CEO & Founder, Gesund.AI
- Lindsay Mateo, CCO, Weave
- Danielle Lauzon, Life Sciences Partner, Co-Chair of Life Sciences M&A, Goodwin
- Michael Buchanio, Managing Director - Deal Advisory & Strategy, KPMG
- Marla Dubinsky, MD, CEO and Co-Founder, Trellus Health Inc.
- Jonathan Bush, CEO, Zus Health
- Reena Pande, MD, Partner, Oxeon
- Chris Wilson, Partner, Co-Chair, Healthcare, Goodwin
- Ross Nelson, Principal, National Healthcare Strategy Leader, KPMG
- Mehran Ahmed, Partner, InTandem Capital
- Ran Zheng, CEO, Landmark Bio
- Sophie McGrath, Partner, Goodwin
- Jason Moran, Managing Director, Healthcare Life Sciences, KPMG
- Bali Muralidhar, Managing Partner, Chief Investment Officer & COO, Abingworth
- Ari Brettman, M.D., Sr. Managing Director, Blackstone Life Sciences
- Amit Sinha, Partner, Global Head of Life Sciences Investing, Goldman Sachs & Co. LLC
- Stuart Cable, Vice-Chair and Global Head of M&A, Goodwin
- E. Eric Tokat, Co-President of Investment Banking, Centerview Partners
- Arman Oruc, Partner, Co-Chair, Antitrust + Competition, Goodwin
- Matt Wetzel, Partner, Life Sciences Regulatory & Compliance Goodwin
- Julie Tibbets, Partner, Chair, Life Sciences Regulatory & Compliance Practice, Goodwin
- Noelle Dubiansky, Partner, Goodwin
- Kristin Ciriello Pothier, US LS Sector Leader, Global Deal Advisory & Strategy HCLS Leader, KPMG
- Daniel Rosan, Chief Financial and Business Officer, Ascidian Therapeutics
- Karen Madden, Chief Technology Officer, MilliporeSigma
- Scott Carter, Associate General Counsel and Head of Business Development Legal, BeiGene USA, Inc.
- Chrissy Finkel, VP of M&A, Baxter
- Rob Masella, Partner, Co-Chair, Public M&A, Goodwin
- Steve Sapletal, Principal, National Advisory Leader, Life Sciences, KPMG
- David Kitterick, Managing Partner, Morgan Stanley
- Steve Walker, Sr Director, Alliance Management and M&A Integration, Eli Lilly and Company
- Soumya (SDR) Dutta Roy, Vice President, Global Integration, Baxter Healthcare Corporation
- Kalli Dircks, Managing Director & Co-Head of Healthcare ECM, Morgan Stanley
- Jennifer Porter, Partner, Goodwin
- Shari Mager, Partner, KPMG
- David Haber, Managing Director, Investment Banking Division; Morgan Stanley
- Brad Dahms, Chief Financial Officer and Chief Business Officer, IDRx, Inc.
- Lisa Haddad, Partner, Goodwin
- Bill Anderson, Senior Managing Director and Global Head of Strategic M&A, Defense, & Shareholder Advisory, Evercore
- Rachael Bushey, Life Sciences Partner, Co-Chair, Philadelphia Office, Goodwin
- Kristin Ciriello Pothier, US LS Sector Leader, Global Deal Advisory & Strategy HCLS Leader, KPMG
Learn More about Life Sciences at Goodwin
Life Sciences Practice
Our Life Sciences practice is uniquely positioned to partner with innovators and investors operating in a fast-moving, technology-driven environment. We work with life sciences companies throughout the corporate lifecycle, as well as with investors, banks, and others in the life sciences ecosystem.
Life Sciences Perspectives Blog
Our Life Sciences Perspectives blog is a resource specifically aimed at addressing your most frequent and pressing issues in this dynamic industry. We provide the insights you need most, including developments on private and public company matters, licensing deals and collaborations, patent and IP matters, FDA and healthcare regulatory compliance, and European and Asian developments for life sciences companies.
Related Content & Attendees
- InsightNovember 8, 2024
Life Sciences M&A Trends for 2023 and 2024 (Through End of Q3) in Greater China
- InsightNovember 4, 2024
New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs
- InsightNovember 1, 2024
Four Steps to Maximize the Value of AI Innovation in Medtech
- InsightNovember 1, 2024
How the EU AI Act Could Affect Medtech Innovation
- InsightOctober 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in the Fourth Quarter of 2024 and Beyond
- InsightSeptember 25, 2024
BIOSECURE Act Timeline
- AlertSeptember 12, 2024
Life Sciences Licensing and M&A Update: Catching Up on Recent Decisions Affecting Commercially Reasonable Efforts Definitions and Post-Patent Expiration Royalty Obligations
- InsightSeptember 5, 2024
Antitrust and Competition Life Sciences Quarterly Update Q2 2024
